Top Markets
Coin of the day
Human Metabolome Technologies, Inc. Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc.

6090
Clasificación en acciones #29370
Human Metabolome Technologies, Inc. is a biotechnology company based in... Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Precio por acción
$3.86
Capitalización bursátil
$21.49M
Cambio (1 día)
-0.17%
Cambio (1 año)
-25.27%
País
JP
Comercio Human Metabolome Technologies, Inc. (6090)

Categoría

Ganancias de Human Metabolome Technologies, Inc. (6090)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Human Metabolome Technologies, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Human Metabolome Technologies, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$1.61B -
AU
- -
CH